Haematology Section, Department of Medicine, University of Padova, Padua, Italy; Veneto Institute of Molecular Medicine, Padua, Italy.
Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Lancet Haematol. 2023 Jul;10(7):e549-e556. doi: 10.1016/S2352-3026(23)00086-8.
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance are three premalignant conditions characterised by the presence of small clonal cell expansions in individuals without symptoms or signs that distinguish the related overt malignancies (chronic lymphocytic leukaemia, multiple myeloma, and T-cell large granular lymphocytic leukaemia). As most individuals with these precursor states never progress to malignancies, considerable interest has arisen in comprehending the steps involved in the progression to malignancy, providing more accurate models to investigate potential mechanisms of early blood cancer identification, prevention, and, possibly, intervention. Single-cell technologies and recent progress in high-throughput sequencing and multiomics approaches have contributed to a better definition of the pathophysiological mechanisms of these premalignant conditions, moving our knowledge in the field forward. In this Viewpoint, we analyse the seemingly shared biological trajectories in these precursor haematological malignancies in search of common pathogenetic events. In particular, we address the issue of interactions between expanding clones and their immune ecosystem, offering new clues that might prompt innovative ideas and inspire further investigations to understand the cellular and molecular dynamics entailing progression into overt malignant disease. The relationships between the non-leukaemic microenvironmental cells and the leukaemic counterpart, and the primary drivers of their initial clonal expansion, represent shared biologies that suggest a common identity among the premalignant conditions considered in this Viewpoint.
单克隆 B 细胞淋巴增生症、意义未明的单克隆丙种球蛋白血症和意义未明的 T 细胞克隆是三种癌前状态,其特征是个体中存在小克隆细胞扩增,但没有区分相关显性恶性肿瘤(慢性淋巴细胞白血病、多发性骨髓瘤和 T 细胞大颗粒淋巴细胞白血病)的症状或体征。由于大多数有这些前驱状态的个体从未进展为恶性肿瘤,因此人们对理解进展为恶性肿瘤的步骤产生了极大的兴趣,提供了更准确的模型来研究早期血液癌识别、预防的潜在机制,以及可能的干预措施。单细胞技术和高通量测序及多组学方法的最新进展有助于更好地定义这些癌前状态的病理生理机制,推动了该领域的知识发展。在本观点中,我们分析了这些前驱血液恶性肿瘤中看似共享的生物学轨迹,以寻找共同的发病事件。特别是,我们解决了不断扩增的克隆与免疫生态系统之间相互作用的问题,提供了新的线索,可能会激发创新思维,并激励进一步的研究,以了解涉及显性恶性疾病进展的细胞和分子动态。非白血病微环境细胞与白血病对应物之间的关系,以及它们初始克隆扩增的主要驱动因素,代表了共同的生物学特征,表明在本观点中考虑的癌前状态具有共同的身份。